Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD

NCT04803305 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04803305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04803305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2021
Completion date
August 9, 2022
Enrollment
18 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

anorexia, breast cancer, cachexia, colorectal cancer, fatigue, loss of appetite, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer